NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

3260.20 -38.70 (-1.17%)

36.87% Gain from 52W Low

57,602 NSE+BSE Volume

NSE 21 Oct, 2026 3:31 PM (IST)

40,739.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Ajanta Pharma is on 30 Oct 2026 for the purpose of Quarterly Results See details

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

31 Jul 2026

3260.20

-1.17%

Solid traction in India and Africa boost performance

Hold: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma (Ajanta)’s Q1FY27 results were ahead of our expectations. India, its core markets, registered organic growth of 24.4% YoY and the Africa branded business grew 29.4%.

Ajanta Pharma Ltd. is trading above its 200 day SMA of 3146.3

Ajanta Pharma Ltd.

30 Jul 2026

3260.20

-1.17%

Strong start to FY27; India/Africa/US drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a better-than-expected 1QFY26, with a 7%/9%/11% beat on our revenue/EBITDA/PAT estimates. Robust revenue growth in the US/India/Africa was partially offset by a decline in the Asia segment.

Ajanta Pharma Ltd. is trading below its 30 day SMA of 3483.8

Ajanta Pharma Ltd.

06 May 2026

3260.20

-1.17%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 26 new launches over the last 12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 15 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launch. Asia branded witnessed negative growth due to geopolitical...

Ajanta Pharma has gained 33.82% in the last 1 Year

Ajanta Pharma Ltd.

06 May 2026

3260.20

-1.17%

Ajanta Pharma (AJP IN) Q4FY26 Result Update Strong FY27 revenue guidance BUY

Buy: Ajanta Pharma Ltd.

Target

Prabhudas Lilladhar

Guided high teen revenue growth for FY27E. Capex guidance of INR 4bn in FY27E. AJP's Q4FY26 EBITDA grew strongly by 26% YoY (INR3.75bn; 26.4% OPM) which was 15% above our estimates. The beat was aided by higher US revenues and margins. The recent in-licensing agreement with Biocon for marketing semaglutide in 26 countries across RoW markets is good fit given its strong existing franchise across these markets. Further AJP's play on high growth branded generics (BGx) market spread across India, Asia and Africa which contributed 70% to total revenue in FY26. Strong annual free...

Ajanta Pharma Ltd. has an average target of 3505.40 from 5 brokers.

Ajanta Pharma Ltd.

06 May 2026

3260.20

-1.17%

Ajanta Pharma (BUY): Strong Earnings; FY27 to be healthier than FY26

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT grew by 15.7%/6.8%/21.5% above our estimates. Tax rate reported at 23% vs expected 25.3%

Ajanta Pharma Ltd. is trading above its 200 day SMA of 3146.3

Ajanta Pharma Ltd.

05 May 2026

3260.20

-1.17%

Strong beat on our 4Q estimates; robust outlook

Buy: Ajanta Pharma Ltd.

Motilal Oswal

Ajanta Pharma (AJP) delivered a better-than-expected 4QFY26, with a 10%/17%/21% beat on our revenue/EBITDA/PAT estimates.

Ajanta Pharma has gained 33.82% in the last 1 Year

Ajanta Pharma Ltd.

01 Feb 2026

3260.20

-1.17%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 16 new launches over the last 9-12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 9-12 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launches. Asia branded on the other hand witnessed...

Number of FII/FPI investors increased from 342 to 353 in Sep 2026 qtr.

Ajanta Pharma Ltd.

31 Jan 2026

3260.20

-1.17%

Ajanta Pharma (BUY): Healthy earnings momentum to continue

Buy: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 7%/12% and 5.6% above our estimates driven by beat across regions. EBITDA margin 130 bps above our estimates

Ajanta Pharma Ltd. has an average target of 3505.40 from 5 brokers.

Ajanta Pharma Ltd.

30 Jan 2026

3260.20

-1.17%

Execution drives earnings beat

buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) posted a better-than-expected financial performance in 3QFY26, with 5%/7%/5% beat on revenue/EBITDA/PAT. AJP saw superior execution in Africa, US and domestic formulation (DF), which was offset to some extent by subdued performance in Asia.

Ajanta Pharma has gained 33.82% in the last 1 Year

Ajanta Pharma Ltd.

29 Dec 2025

3260.20

-1.17%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Ajanta Pharma Ltd. is trading below its 30 day SMA of 3483.8

Is Ajanta Pharma Ltd. worth buying?

197 Votes:

Buy 77.16%

Sell 16.24%

Hold 6.6%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf